Table 5.
Predictors of cancer-specific mortality in patients with castration-resistant prostate cancer
| Univariate | Multivariate | |||||
|---|---|---|---|---|---|---|
| HR | (95% CI) | P | HR | (95% CI) | p | |
| Age | 1.038 | (1.016–1.061) | 0.001 | 1.020 | (0.998–1.042) | 0.069 |
| Body mass index | 0.968 | (0.901–1.041) | 0.382 | |||
| PSAa | 1.001 | (1.000-1.001) | < 0.001 | 1.001 | (1.000–1.001) | 0.018 |
| Hemoglobina | 1.001 | (0.999-1.002) | 0.306 | |||
| Albumina | 0.408 | (0.301-0.553) | < 0.001 | |||
| Alkaline phosphatasea | 1.001 | (1.000–1.001) | < 0.001 | 1.001 | (1.001–1.002) | < 0.001 |
| T stage (≥T3 vs. ≤T2) | 0.865 | (0.524–1.430) | 0.271 | |||
| N stage (1 vs. 0) | 1.251 | (0.922–1.697) | 0.152 | |||
| M stage (1 vs. 0) | 1.528 | (0.983–2.376) | 0.062 | |||
| Gleason score (≥8 vs. ≤7) | 1.957 | (1.441–2.658) | < 0.001 | 2.004 | (1.452–2.767) | < 0.001 |
| CCI ≥4 | 1.197 | (0.811–1.765) | 0.365 | |||
| ECOG ≥2 | 1.802 | (1.216–2.670) | 0.003 | 1.304 | (1.164–2.158) | 0.035 |
| Docetaxel cycles | 0.926 | (0.900–0.953) | 0.026 | 0.943 | (0.915–0.972) | 0.011 |
| Primary treatment | ||||||
| Prostatectomy | 1 | (reference) | ||||
| Radiation therapy | 0.778 | (0.580–1.141) | 0.584 | |||
| ARAT agent sequencing | ||||||
| Pre-chemotherapy | 1 | (reference) | ||||
| Post-chemotherapy | 0.865 | (0.524–1.430) | 0.572 | |||
| Radium-223 administration | 0.803 | (0.255–2.527) | 0.707 | |||
| Clinical trial participation | 0.593 | (0.417–0.843) | 0.004 | 0.585 | (0.429–0.797) | 0.038 |
aLaboratory values at diagnosis of castration-resistant prostate cancer
Abbreviations: ARAT androgen receptor axis-targeted, CI confidence interval, CCI Charlson Comorbidity Index, ECOG PS Eastern Cooperative Oncology Group performance status, HR hazard ratio, PSA prostate-specific antigen